Splenin
A Khavinson-class ultrashort spleen peptide bioregulator investigated for immune restoration and normalization of blood cell production.
Splenin is a synthetic ultrashort peptide (Lys-Glu-Asp, KED) classified as a Khavinson-class bioregulator targeted at splenic and immune tissue. It is investigated for immunomodulatory and cytoprotective properties through proposed gene-expression regulatory mechanisms in lymphoid and hematopoietic cell populations, including normalization of leukocyte and platelet production. Evidence is early-stage and derives largely from Khavinson-series and class-level research rather than independent Western clinical trials.
Class
Synthetic ultrashort peptide bioregulator (Khavinson class)
Half-life
Unknown
Routes
Subcutaneous, Intramuscular
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Immune restoration
Splenin is proposed to modulate splenic immune cell activity and support restoration of immune function, consistent with the tissue-specific action attributed to Khavinson bioregulator peptides. Evidence is preclinical and class-level.
Blood cell production support
The peptide is described as normalizing leukocyte and platelet production, reflecting a proposed regulatory effect on hematopoietic progenitor populations in the spleen and marrow.
Splenic function support
As a spleen-targeted bioregulator, splenin is investigated for supporting normal splenic immune cell activity and cytoprotection in lymphoid tissue.
Mechanism
How it works
Splenin is an ultrashort peptide (Lys-Glu-Asp, KED) belonging to the Khavinson class of tissue-specific bioregulators. Like other peptides in this class, it is proposed to modulate gene expression in target immune cells via epigenetic mechanisms rather than acting through a classical receptor pathway.
Published research on the class demonstrates that ultrashort peptides can influence differentiation of stem and progenitor cells and regulate gene activity in aging tissues. Splenin is proposed to act on splenic and hematopoietic cell populations within this framework, normalizing leukocyte and platelet production and modulating immune cell activity.
Class-level studies have characterized neuroepigenetic mechanisms of ultrashort peptides in neurodegeneration models and shown peptide-driven regulation of cell differentiation, including interactions with histone proteins, DNA regulatory elements, and non-coding RNAs. These provide the mechanistic context in which splenin's tissue-specific immunomodulatory activity is hypothesized.
Evidence
Research & clinical studies (2)
Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease
Reviews proposed epigenetic mechanisms by which ultrashort Khavinson peptides such as splenin may act through interactions with histone proteins, DNA regulatory elements, and non-coding RNAs.
PMID 35457077Peptide Regulation of Cell Differentiation
Summarizes evidence that short peptides of 2 to 7 amino acids regulate differentiation of immune, neural, epithelial, and stem cells by modulating histone accessibility, DNA methylation, and signaling pathways.
PMID 31808038Safety
Side effects & considerations
Splenin is generally considered lower risk in research contexts, with no well-established contraindications reported in the reviewed sources. Individual response varies, and safety data are limited to early-stage and class-level research.
FAQ
Splenin — common questions
What is Splenin?
Splenin is a synthetic ultrashort peptide (Lys-Glu-Asp, KED) classified as a Khavinson-class bioregulator targeted at splenic and immune tissue. It is investigated for immunomodulatory and cytoprotective properties through proposed gene-expression regulatory mechanisms in lymphoid and hematopoietic cell populations.
What is Splenin primarily studied for?
It is primarily studied for immune restoration, blood cell production, and splenic function support.
What are the reported benefits of Splenin?
Research on splenin primarily documents effects related to immune restoration, normalization of leukocyte and platelet production, and support of splenic immune cell activity. These derive from preclinical and class-level literature, and individual response varies.
What are the side effects of Splenin?
No well-established contraindications or side effects were reported in the reviewed sources. It is considered lower risk in research contexts, but safety data remain limited.
Is Splenin approved or legal?
Splenin has no FDA approval, NDA, or IND and is not on any FDA list. It is a Russian-origin peptide bioregulator treated as a research chemical in the United States.
How is Splenin administered?
The sources list subcutaneous and intramuscular administration as the investigated routes. No validated human dosing protocol has been published in Western-indexed literature.
